Women's Health News

RSS

New HPV self-test approach could enhance cervical cancer screening

Analyses of self-tests for human papillomavirus (HPV) can be used to divide HPV-positive women into three risk groups, according to a new study from Karolinska Institutet and Queen Mary University of London published in PLOS Medicine.

13 Dec 2024

Potential new mRNA-based therapy for pre-eclampsia

Lipid nanoparticles targeting VEGF mRNA show promise in treating pre-eclampsia, restoring maternal blood pressure and enhancing fetal health in murine models.

13 Dec 2024

Nutrition progress stalls: Most nations lag behind 2030 goals

Global progress toward nutrition targets is slow, with few countries on track to meet goals for anemia, stunting, and child overweight by 2030, highlighting the urgent need for long-term, multisectoral strategies.

12 Dec 2024

Herpes infections soar globally as new study reveals massive disease burden

Global estimates of HSV-1 and HSV-2 reveal a staggering disease burden, with 42.4 million new genital herpes cases and 8.8 billion GUD person-days in 2020, underscoring the urgent need for improved prevention strategies.

12 Dec 2024

Metastatic breast cancer rates surge across U.S. women, exposing disparities and pandemic impacts

Metastatic breast cancer diagnoses are rising in U.S. women, especially in younger age groups and racial minorities, as revealed by SEER data from 2004–2021. The study highlights disparities and COVID-19's impact, urging systemic changes to improve early detection and healthcare equity.

12 Dec 2024

Circadian chaos: How transportation noise harms heart health

Transportation noise poses serious risks to cardiovascular health, causing inflammation, oxidative stress, and circadian rhythm disruption, with compounded effects from air pollution.

12 Dec 2024

Caregiver stress may increase hypertension risk in Black women

A new analysis finds that the stress of being a caregiver is associated with an increased risk of developing high blood pressure in 21- to 44-year-old Black women, a group known to have a higher prevalence of the condition compared with women of other racial and ethnic groups.

12 Dec 2024

Chest wall irradiation does not impact 10-year survival in intermediate-risk breast cancer

Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent chest wall irradiation (CWI) after mastectomy, according to results from the BIG 2-04 MRC SUPREMO clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Gene therapy to prevent stillbirth and premature delivery developed

Researchers investigate the effectiveness of placental nano-based insulin-like 1 growth factor gene therapy to correct fetal growth restriction.

12 Dec 2024

Scientists reveal the secret of female orgasm

The secret of the female orgasm may have been revealed by scientists in a pioneering study.

11 Dec 2024

Understanding how angiogenesis contributes to drug resistance in breast cancer

Breast cancer, the most common cancer among women, is notorious for its ability to develop resistance to a wide range of treatments, including surgery, chemotherapy, targeted therapies, and immunotherapy.

11 Dec 2024

Groundbreaking research offers hope for pregnant people with pre-eclampsia

Penn Engineers have made a critical breakthrough that bridges a major healthy equity gap for pregnant people with pre-eclampsia, a condition that arises due to insufficient blood flow to the placenta and results in high maternal blood pressure and restricted blood flow to the fetus.

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Risk-reducing surgeries provide benefits for young BRCA-mutation carriers

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing salpingo-oophorectomy (RRSO) had lower rates of recurrence, secondary breast and/or ovarian malignancies, and death than those who did not undergo these surgeries, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Weight gain after 35 linked to increased breast cancer risk

The body mass index (BMI) has long been used to measure body fat, but its influence on breast cancer risk is more complex than previously thought.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024